Global Dystrophic Epidermolysis Bullosa Treatment Market

Dystrophic Epidermolysis Bullosa Treatment Comprehensive Study by Therapy (Gene therapy, Bone Marrow (Stem Cell) Transplantation, Protein Replacement Therapies, Cell-based Therapies), Treatment (Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, Others), Category (Dominant Dystrophic Epidermolysis Bullosa (DDEB), Recessive Dystrophic Epidermolysis Bullosa (RDEB)), End Use (Hospitals, Specialty Clinics, Over-the-Counter (OTC)) Players and Region - Global Market Outlook to 2028

Dystrophic Epidermolysis Bullosa Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dystrophic Epidermolysis Bullosa Treatment
Epidermolysis bullosa (EB) is a category of inherited blistering skin diseases. Although the community is clinically and genetically diverse, both EB types are linked to mechanically induced skin blistering and fragility. Some EB forms have documented causative gene mutations. EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome are all forms of EB (KS). The morphological stage of blister formation is used to classify blisters. However, over the last decade, a number of significant developments have been made that push the clinic closer to modern therapeutic approaches that include gene therapy, protein replacement therapy, cell therapy (allogeneic fibroblasts, Mesenchymal Stromal Cells (MSCs), bone marrow stem cell transplant, revertant mosaic keratinocyte culture/vaccination, gene editing/engineering, and the clinical application of inducible pluripotent stem cells).

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Dystrophic Epidermolysis Bullosa Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Krystal Biotech (United States), Castle Creek Biosciences, Inc. (United States), Abeona Therapeutics, Inc. (United States), Amryt Pharma plc (United Kingdom), Wings Therapeutics (United States), Phoenix Tissue Repair (United States), InMed Pharmaceuticals, Inc. (Canada), RegeneRx (United States) and Holostem Terapie Avanzate S.r.l. (Italy) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer Inc. (United States), Galderma International (Switzerland), Mylan N.V. (Netherland) and ConvaTec (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global Dystrophic Epidermolysis Bullosa Treatment market by and Region.



On the basis of geography, the market of Dystrophic Epidermolysis Bullosa Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Gene therapy will boost the Dystrophic Epidermolysis Bullosa Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Antibiotics will boost the Dystrophic Epidermolysis Bullosa Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Category, the sub-segment i.e. Dominant Dystrophic Epidermolysis Bullosa (DDEB) will boost the Dystrophic Epidermolysis Bullosa Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Dystrophic Epidermolysis Bullosa Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Advance Therapeutics and Effective Medication

Market Growth Drivers:
Prevalence of Dystrophic Epidermolysis Bullosa, Rising Geriatric Population and Increasing Healthcare Infrastructure

Challenges:
Lack of Trained Professionals

Restraints:
High-Cost Expenses

Opportunities:
Growing Demand in Emerging Regions Particularly Asia

Market Leaders and their expansionary development strategies
In October 2023, DEB patient advocacy groups form a global alliance this initiative aims to unite the DEB community, share resources, and advocate for improved research funding and access to treatment for all patients worldwide.
In September 2023, AlloVir receives Fast Track designation from FDA for ALTO-101 this cell therapy candidate uses genetically modified T cells to target and eliminate the faulty immune cells responsible for blistering in DEB, potentially offering a personalized and disease-modifying treatment.


Key Target Audience
Dystrophic Epidermolysis Bullosa Treatment Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Therapy
  • Gene therapy
  • Bone Marrow (Stem Cell) Transplantation
  • Protein Replacement Therapies
  • Cell-based Therapies

By Treatment
  • Antibiotics
  • Corticosteroids
  • Opioid Analgesics
  • Anticonvulsant
  • Others

By Category
  • Dominant Dystrophic Epidermolysis Bullosa (DDEB)
  • Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By End Use
  • Hospitals
  • Specialty Clinics
  • Over-the-Counter (OTC)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Dystrophic Epidermolysis Bullosa
      • 3.2.2. Rising Geriatric Population
      • 3.2.3. Increasing Healthcare Infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Therapeutics and Effective Medication
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dystrophic Epidermolysis Bullosa Treatment, by Therapy, Treatment, Category, End Use and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dystrophic Epidermolysis Bullosa Treatment (Value)
      • 5.2.1. Global Dystrophic Epidermolysis Bullosa Treatment by: Therapy (Value)
        • 5.2.1.1. Gene therapy
        • 5.2.1.2. Bone Marrow (Stem Cell) Transplantation
        • 5.2.1.3. Protein Replacement Therapies
        • 5.2.1.4. Cell-based Therapies
      • 5.2.2. Global Dystrophic Epidermolysis Bullosa Treatment by: Treatment (Value)
        • 5.2.2.1. Antibiotics
        • 5.2.2.2. Corticosteroids
        • 5.2.2.3. Opioid Analgesics
        • 5.2.2.4. Anticonvulsant
        • 5.2.2.5. Others
      • 5.2.3. Global Dystrophic Epidermolysis Bullosa Treatment by: Category (Value)
        • 5.2.3.1. Dominant Dystrophic Epidermolysis Bullosa (DDEB)
        • 5.2.3.2. Recessive Dystrophic Epidermolysis Bullosa (RDEB)
      • 5.2.4. Global Dystrophic Epidermolysis Bullosa Treatment by: End Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Clinics
        • 5.2.4.3. Over-the-Counter (OTC)
      • 5.2.5. Global Dystrophic Epidermolysis Bullosa Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dystrophic Epidermolysis Bullosa Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Krystal Biotech (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Castle Creek Biosciences, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abeona Therapeutics, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amryt Pharma plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Wings Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Phoenix Tissue Repair (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. InMed Pharmaceuticals, Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. RegeneRx (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Holostem Terapie Avanzate S.r.l. (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Dystrophic Epidermolysis Bullosa Treatment Sale, by Therapy, Treatment, Category, End Use and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dystrophic Epidermolysis Bullosa Treatment (Value)
      • 7.2.1. Global Dystrophic Epidermolysis Bullosa Treatment by: Therapy (Value)
        • 7.2.1.1. Gene therapy
        • 7.2.1.2. Bone Marrow (Stem Cell) Transplantation
        • 7.2.1.3. Protein Replacement Therapies
        • 7.2.1.4. Cell-based Therapies
      • 7.2.2. Global Dystrophic Epidermolysis Bullosa Treatment by: Treatment (Value)
        • 7.2.2.1. Antibiotics
        • 7.2.2.2. Corticosteroids
        • 7.2.2.3. Opioid Analgesics
        • 7.2.2.4. Anticonvulsant
        • 7.2.2.5. Others
      • 7.2.3. Global Dystrophic Epidermolysis Bullosa Treatment by: Category (Value)
        • 7.2.3.1. Dominant Dystrophic Epidermolysis Bullosa (DDEB)
        • 7.2.3.2. Recessive Dystrophic Epidermolysis Bullosa (RDEB)
      • 7.2.4. Global Dystrophic Epidermolysis Bullosa Treatment by: End Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Clinics
        • 7.2.4.3. Over-the-Counter (OTC)
      • 7.2.5. Global Dystrophic Epidermolysis Bullosa Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dystrophic Epidermolysis Bullosa Treatment: by Therapy(USD Million)
  • Table 2. Dystrophic Epidermolysis Bullosa Treatment Gene therapy , by Region USD Million (2017-2022)
  • Table 3. Dystrophic Epidermolysis Bullosa Treatment Bone Marrow (Stem Cell) Transplantation , by Region USD Million (2017-2022)
  • Table 4. Dystrophic Epidermolysis Bullosa Treatment Protein Replacement Therapies , by Region USD Million (2017-2022)
  • Table 5. Dystrophic Epidermolysis Bullosa Treatment Cell-based Therapies , by Region USD Million (2017-2022)
  • Table 6. Dystrophic Epidermolysis Bullosa Treatment: by Treatment(USD Million)
  • Table 7. Dystrophic Epidermolysis Bullosa Treatment Antibiotics , by Region USD Million (2017-2022)
  • Table 8. Dystrophic Epidermolysis Bullosa Treatment Corticosteroids , by Region USD Million (2017-2022)
  • Table 9. Dystrophic Epidermolysis Bullosa Treatment Opioid Analgesics , by Region USD Million (2017-2022)
  • Table 10. Dystrophic Epidermolysis Bullosa Treatment Anticonvulsant , by Region USD Million (2017-2022)
  • Table 11. Dystrophic Epidermolysis Bullosa Treatment Others , by Region USD Million (2017-2022)
  • Table 12. Dystrophic Epidermolysis Bullosa Treatment: by Category(USD Million)
  • Table 13. Dystrophic Epidermolysis Bullosa Treatment Dominant Dystrophic Epidermolysis Bullosa (DDEB) , by Region USD Million (2017-2022)
  • Table 14. Dystrophic Epidermolysis Bullosa Treatment Recessive Dystrophic Epidermolysis Bullosa (RDEB) , by Region USD Million (2017-2022)
  • Table 15. Dystrophic Epidermolysis Bullosa Treatment: by End Use(USD Million)
  • Table 16. Dystrophic Epidermolysis Bullosa Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 17. Dystrophic Epidermolysis Bullosa Treatment Specialty Clinics , by Region USD Million (2017-2022)
  • Table 18. Dystrophic Epidermolysis Bullosa Treatment Over-the-Counter (OTC) , by Region USD Million (2017-2022)
  • Table 19. South America Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2017-2022)
  • Table 20. South America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 21. South America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 22. South America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 23. South America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 24. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 25. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 26. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 27. Brazil Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 28. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 29. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 30. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 31. Argentina Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 32. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 33. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 34. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 35. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 36. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 38. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 39. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 40. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 41. China Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 42. China Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 43. China Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 44. China Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 45. Japan Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 46. Japan Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 47. Japan Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 48. Japan Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 49. India Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 50. India Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 51. India Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 52. India Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 53. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 54. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 55. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 56. South Korea Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 57. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 58. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 59. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 60. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 61. Australia Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 62. Australia Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 63. Australia Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 64. Australia Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 69. Europe Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2017-2022)
  • Table 70. Europe Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 71. Europe Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 72. Europe Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 73. Europe Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 74. Germany Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 75. Germany Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 76. Germany Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 77. Germany Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 78. France Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 79. France Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 80. France Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 81. France Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 82. Italy Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 83. Italy Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 84. Italy Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 85. Italy Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 86. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 87. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 88. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 89. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 90. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 91. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 92. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 93. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 94. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 95. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 96. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 97. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 98. MEA Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2017-2022)
  • Table 99. MEA Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 100. MEA Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 101. MEA Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 102. MEA Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 103. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 104. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 105. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 106. Middle East Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 107. Africa Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 108. Africa Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 109. Africa Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 110. Africa Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 111. North America Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2017-2022)
  • Table 112. North America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 113. North America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 114. North America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 115. North America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 116. United States Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 117. United States Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 118. United States Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 119. United States Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 120. Canada Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 121. Canada Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 122. Canada Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 123. Canada Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 124. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2017-2022)
  • Table 125. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2017-2022)
  • Table 126. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2017-2022)
  • Table 127. Mexico Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2017-2022)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Dystrophic Epidermolysis Bullosa Treatment: by Therapy(USD Million)
  • Table 138. Dystrophic Epidermolysis Bullosa Treatment Gene therapy , by Region USD Million (2023-2028)
  • Table 139. Dystrophic Epidermolysis Bullosa Treatment Bone Marrow (Stem Cell) Transplantation , by Region USD Million (2023-2028)
  • Table 140. Dystrophic Epidermolysis Bullosa Treatment Protein Replacement Therapies , by Region USD Million (2023-2028)
  • Table 141. Dystrophic Epidermolysis Bullosa Treatment Cell-based Therapies , by Region USD Million (2023-2028)
  • Table 142. Dystrophic Epidermolysis Bullosa Treatment: by Treatment(USD Million)
  • Table 143. Dystrophic Epidermolysis Bullosa Treatment Antibiotics , by Region USD Million (2023-2028)
  • Table 144. Dystrophic Epidermolysis Bullosa Treatment Corticosteroids , by Region USD Million (2023-2028)
  • Table 145. Dystrophic Epidermolysis Bullosa Treatment Opioid Analgesics , by Region USD Million (2023-2028)
  • Table 146. Dystrophic Epidermolysis Bullosa Treatment Anticonvulsant , by Region USD Million (2023-2028)
  • Table 147. Dystrophic Epidermolysis Bullosa Treatment Others , by Region USD Million (2023-2028)
  • Table 148. Dystrophic Epidermolysis Bullosa Treatment: by Category(USD Million)
  • Table 149. Dystrophic Epidermolysis Bullosa Treatment Dominant Dystrophic Epidermolysis Bullosa (DDEB) , by Region USD Million (2023-2028)
  • Table 150. Dystrophic Epidermolysis Bullosa Treatment Recessive Dystrophic Epidermolysis Bullosa (RDEB) , by Region USD Million (2023-2028)
  • Table 151. Dystrophic Epidermolysis Bullosa Treatment: by End Use(USD Million)
  • Table 152. Dystrophic Epidermolysis Bullosa Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 153. Dystrophic Epidermolysis Bullosa Treatment Specialty Clinics , by Region USD Million (2023-2028)
  • Table 154. Dystrophic Epidermolysis Bullosa Treatment Over-the-Counter (OTC) , by Region USD Million (2023-2028)
  • Table 155. South America Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2023-2028)
  • Table 156. South America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 157. South America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 158. South America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 159. South America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 160. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 161. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 162. Brazil Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 163. Brazil Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 164. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 165. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 166. Argentina Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 167. Argentina Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 168. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 169. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 170. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 171. Rest of South America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 172. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2023-2028)
  • Table 173. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 174. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 175. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 176. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 177. China Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 178. China Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 179. China Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 180. China Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 181. Japan Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 182. Japan Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 183. Japan Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 184. Japan Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 185. India Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 186. India Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 187. India Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 188. India Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 189. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 190. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 191. South Korea Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 192. South Korea Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 193. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 194. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 195. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 196. Taiwan Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 197. Australia Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 198. Australia Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 199. Australia Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 200. Australia Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 205. Europe Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2023-2028)
  • Table 206. Europe Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 207. Europe Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 208. Europe Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 209. Europe Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 210. Germany Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 211. Germany Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 212. Germany Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 213. Germany Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 214. France Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 215. France Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 216. France Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 217. France Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 218. Italy Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 219. Italy Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 220. Italy Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 221. Italy Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 222. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 223. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 224. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 225. United Kingdom Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 226. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 227. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 228. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 229. Netherlands Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 230. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 231. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 232. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 233. Rest of Europe Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 234. MEA Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2023-2028)
  • Table 235. MEA Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 236. MEA Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 237. MEA Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 238. MEA Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 239. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 240. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 241. Middle East Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 242. Middle East Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 243. Africa Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 244. Africa Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 245. Africa Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 246. Africa Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 247. North America Dystrophic Epidermolysis Bullosa Treatment, by Country USD Million (2023-2028)
  • Table 248. North America Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 249. North America Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 250. North America Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 251. North America Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 252. United States Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 253. United States Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 254. United States Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 255. United States Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 256. Canada Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 257. Canada Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 258. Canada Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 259. Canada Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 260. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Therapy USD Million (2023-2028)
  • Table 261. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Treatment USD Million (2023-2028)
  • Table 262. Mexico Dystrophic Epidermolysis Bullosa Treatment, by Category USD Million (2023-2028)
  • Table 263. Mexico Dystrophic Epidermolysis Bullosa Treatment, by End Use USD Million (2023-2028)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dystrophic Epidermolysis Bullosa Treatment: by Therapy USD Million (2017-2022)
  • Figure 5. Global Dystrophic Epidermolysis Bullosa Treatment: by Treatment USD Million (2017-2022)
  • Figure 6. Global Dystrophic Epidermolysis Bullosa Treatment: by Category USD Million (2017-2022)
  • Figure 7. Global Dystrophic Epidermolysis Bullosa Treatment: by End Use USD Million (2017-2022)
  • Figure 8. South America Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 10. Europe Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 11. MEA Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 12. North America Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 13. Global Dystrophic Epidermolysis Bullosa Treatment share by Players 2022 (%)
  • Figure 14. Global Dystrophic Epidermolysis Bullosa Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Dystrophic Epidermolysis Bullosa Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Krystal Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 18. Krystal Biotech (United States) Revenue: by Geography 2022
  • Figure 19. Castle Creek Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Castle Creek Biosciences, Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Abeona Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abeona Therapeutics, Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Amryt Pharma plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Amryt Pharma plc (United Kingdom) Revenue: by Geography 2022
  • Figure 25. Wings Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 26. Wings Therapeutics (United States) Revenue: by Geography 2022
  • Figure 27. Phoenix Tissue Repair (United States) Revenue, Net Income and Gross profit
  • Figure 28. Phoenix Tissue Repair (United States) Revenue: by Geography 2022
  • Figure 29. InMed Pharmaceuticals, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 30. InMed Pharmaceuticals, Inc. (Canada) Revenue: by Geography 2022
  • Figure 31. RegeneRx (United States) Revenue, Net Income and Gross profit
  • Figure 32. RegeneRx (United States) Revenue: by Geography 2022
  • Figure 33. Holostem Terapie Avanzate S.r.l. (Italy) Revenue, Net Income and Gross profit
  • Figure 34. Holostem Terapie Avanzate S.r.l. (Italy) Revenue: by Geography 2022
  • Figure 35. Global Dystrophic Epidermolysis Bullosa Treatment: by Therapy USD Million (2023-2028)
  • Figure 36. Global Dystrophic Epidermolysis Bullosa Treatment: by Treatment USD Million (2023-2028)
  • Figure 37. Global Dystrophic Epidermolysis Bullosa Treatment: by Category USD Million (2023-2028)
  • Figure 38. Global Dystrophic Epidermolysis Bullosa Treatment: by End Use USD Million (2023-2028)
  • Figure 39. South America Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 40. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 41. Europe Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 42. MEA Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
  • Figure 43. North America Dystrophic Epidermolysis Bullosa Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Krystal Biotech (United States)
  • Castle Creek Biosciences, Inc. (United States)
  • Abeona Therapeutics, Inc. (United States)
  • Amryt Pharma plc (United Kingdom)
  • Wings Therapeutics (United States)
  • Phoenix Tissue Repair (United States)
  • InMed Pharmaceuticals, Inc. (Canada)
  • RegeneRx (United States)
  • Holostem Terapie Avanzate S.r.l. (Italy)
Additional players considered in the study are as follows:
Pfizer Inc. (United States) , Galderma International (Switzerland) , Mylan N.V. (Netherland) , ConvaTec (United Kingdom)
Select User Access Type

Key Highlights of Report


Dec 2023 248 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dystrophic Epidermolysis Bullosa Treatment Market Quantitative research analysis
Global Dystrophic Epidermolysis Bullosa Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Krystal Biotech (United States), Castle Creek Biosciences, Inc. (United States), Abeona Therapeutics, Inc. (United States), Amryt Pharma plc (United Kingdom), Wings Therapeutics (United States), Phoenix Tissue Repair (United States), InMed Pharmaceuticals, Inc. (Canada), RegeneRx (United States) and Holostem Terapie Avanzate S.r.l. (Italy) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence of Advance Therapeutics and Effective Medication" is seen as one of major influencing trends for Dystrophic Epidermolysis Bullosa Treatment Market during projected period 2022-2028.
The Dystrophic Epidermolysis Bullosa Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dystrophic Epidermolysis Bullosa Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Cutaneous T-cell Lymphomas (CTCL) Comprehensive Study by Type (Mycosis Fungoides (MF), Sezary Syndrome (SS), Others), Treatment (Radiation Therapy, Chemotherapy, Immunotherapy, Targeted therapy, Othe...
$ 3500
Lichen Nitidus Treatment Comprehensive Study by Type (Corticosteroids, Retinoid, Antihistamines, Phototherapy), Route of Administration (Topical, Oral), Diagnosis (Electrocardiogram, Electrophysiolog...
$ 3450
Breast Cancer Diagnostics Comprehensive Study by Type (Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomo...
$ 3750
Dyspnea Treatment Comprehensive Study by Type (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others)), App...
$ 3650
Reflux Nephropathy Treatment Comprehensive Study by Type (Prophylactic Antibiotics, Antihypertensive Medications, Pain Medications, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmac...
$ 3350
Reperfusion Injury Comprehensive Study by Application (Heart Injury, Kidney Injury, Intestine Injury, Others), Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulfid...
$ 3450